Chronic myelomonocytic leukaemia program in Pharmaceutical Benefits Scheme (PBS) 012-22062453
Expand allThis document outlines details of PBS-subsidised azacitidine and decitabine+cedazuridine for patients with chronic myelomonocytic leukaemia (CMML).
Chronic myelomonocytic leukaemia and listing dates
Chronic myelomonocytic leukaemia is a chronic blood cancer in which a person’s bone marrow creates too many monocytes, a type of white blood cell.
Listing dates are:
- azacitidine - 1 February 2011, and
- decitabine+cedazuridine - 1 October 2022
See Written Authority Required Drugs for more details.
Enquiries
- Transfer enquiries about prescription arrangements for azacitidine to the PBS Complex Drugs Programs team and choose the option relevant to the condition treated
- Transfer enquiries about prescription arrangements for decitabine+cedazuridine to PBS authority approvals
The Resources page contains:
- application forms
- contact details
- restriction and item codes
- the PBS schedule
- Services Australia website link
Related links
Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)
Processing an existing Authority request in the Pharmaceutical Benefits Scheme (PBS)